ATE529750T1 - Stimulatorische autoantikörper gegen den pdgf- rezeptor als pathologische marker und therapeutisches target - Google Patents

Stimulatorische autoantikörper gegen den pdgf- rezeptor als pathologische marker und therapeutisches target

Info

Publication number
ATE529750T1
ATE529750T1 AT06796239T AT06796239T ATE529750T1 AT E529750 T1 ATE529750 T1 AT E529750T1 AT 06796239 T AT06796239 T AT 06796239T AT 06796239 T AT06796239 T AT 06796239T AT E529750 T1 ATE529750 T1 AT E529750T1
Authority
AT
Austria
Prior art keywords
pdgf receptor
therapeutic target
autoantibodies against
pathological marker
erk1
Prior art date
Application number
AT06796239T
Other languages
English (en)
Inventor
Vittorio Enrico Avvedimento
Gabrielli Armando
Mariarosa Santillo
Ada Funaro
Michele Luchetti
Baroni Silvia Svegliati
Original Assignee
Vittorio Enrico Avvedimento
Gabrielli Armando
Mariarosa Santillo
Ada Funaro
Michele Luchetti
Baroni Silvia Svegliati
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vittorio Enrico Avvedimento, Gabrielli Armando, Mariarosa Santillo, Ada Funaro, Michele Luchetti, Baroni Silvia Svegliati filed Critical Vittorio Enrico Avvedimento
Application granted granted Critical
Publication of ATE529750T1 publication Critical patent/ATE529750T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders
    • G01N2800/245—Transplantation related diseases, e.g. graft versus host disease
AT06796239T 2005-07-28 2006-07-28 Stimulatorische autoantikörper gegen den pdgf- rezeptor als pathologische marker und therapeutisches target ATE529750T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70337705P 2005-07-28 2005-07-28
PCT/IT2006/000587 WO2007013124A2 (en) 2005-07-28 2006-07-28 Stimulatory auto-antibodies to the pdgf receptor as pathology marker and therapeutic target

Publications (1)

Publication Number Publication Date
ATE529750T1 true ATE529750T1 (de) 2011-11-15

Family

ID=37683748

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06796239T ATE529750T1 (de) 2005-07-28 2006-07-28 Stimulatorische autoantikörper gegen den pdgf- rezeptor als pathologische marker und therapeutisches target

Country Status (8)

Country Link
US (2) US20090221481A1 (de)
EP (1) EP1907851B1 (de)
JP (1) JP2009503493A (de)
KR (1) KR20080077347A (de)
CN (1) CN101517414A (de)
AT (1) ATE529750T1 (de)
CA (1) CA2616963A1 (de)
WO (1) WO2007013124A2 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008090213A1 (en) * 2007-01-25 2008-07-31 Mariarosaria Santillo Methods to diagnose an autoimmune disease and to identify and isolate stimulatory molecules
WO2012013813A1 (en) 2010-07-30 2012-02-02 Gianluca Moroncini Epitopes of the human pdgf receptor able to bind human auto-antibodies, antibodies and uses thereof
US20150355191A1 (en) * 2012-07-11 2015-12-10 Biomimetic Therapeutics, Llc Cell-Based Assay for Neutralizing Antibodies
JP2015528912A (ja) * 2012-07-23 2015-10-01 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 強皮症の診断方法
RU2015115956A (ru) * 2012-11-09 2017-01-10 Пфайзер Инк. Антитела, специфичные в отношении фактора роста тромбоцитов в, и их композиции и применения
WO2020037378A1 (en) * 2018-08-24 2020-02-27 The Flinders University Of South Australia Detection of functional autoantibodies

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0325224B1 (de) * 1988-01-22 1996-07-31 ZymoGenetics, Inc. Verfahren zur Herstellung von sekretierten Rezeptoranalogen
US5268358A (en) * 1988-12-08 1993-12-07 Cor Therapeutics, Inc. PDGF receptor blocking peptides
CA2138932A1 (en) * 1993-12-28 1995-06-29 Masako Wagatsuma Mutant proteins of human dna topoisomerase i
JP3472048B2 (ja) * 1995-10-09 2003-12-02 鐘淵化学工業株式会社 自己免疫疾患の診断薬
EP1340077B1 (de) * 2000-10-17 2006-01-25 Besst-Test ApS Test zum direkten nachweis eines inflammatorischen anzeiger in einer körperflüssigkeitsprobe
JP3455782B2 (ja) * 2001-12-27 2003-10-14 学校法人慶應義塾 強皮症の診断薬

Also Published As

Publication number Publication date
JP2009503493A (ja) 2009-01-29
WO2007013124A2 (en) 2007-02-01
EP1907851B1 (de) 2011-10-19
EP1907851A2 (de) 2008-04-09
CN101517414A (zh) 2009-08-26
KR20080077347A (ko) 2008-08-22
US20090221481A1 (en) 2009-09-03
CA2616963A1 (en) 2007-02-01
WO2007013124A8 (en) 2007-09-27
WO2007013124A3 (en) 2007-07-19
US20120252037A1 (en) 2012-10-04

Similar Documents

Publication Publication Date Title
CY1120014T1 (el) Αντισωματα συνδεσης πρωτοϊνιδιου και χρηση αυτων σε θεραπευτικες και διαγνωστικες μεθοδους για ασθενεια parkinson, ανοια με σωματα lewy και αλλες αλφα-συνουκλεϊνοπαθειες
BRPI0510274B8 (pt) uso de um agente para tratar ou prevenir doença celíaca, composição farmacêutica compreendendo dito agente, método de diagnóstico de doença celíaca, ou suscetibilidade à doença celíaca, uso do dito agente para a preparação de um meio de diagnóstico e kit para realizar o dito método de diagnóstico
BRPI0519047A2 (pt) mÉtodo para a produÇço de um agente de contraste marcador ou agente terapÊutico marcador, agentes de contraste marcadores e uso de agentes de contraste marcadores ou de agentes terapÊuticos marcadores
WO2006063093A3 (en) Methods for diagnosis and treatment of crohn's disease
ATE529750T1 (de) Stimulatorische autoantikörper gegen den pdgf- rezeptor als pathologische marker und therapeutisches target
EA200801071A1 (ru) Способы и композиции для применения в целях лечения пациентов с положительным по аутоантителам заболеванием
FR16C0021I2 (fr) Azetidines en tant qu'inhibiteurs de mek et leur utilisation pour le traitement des maladies proliferatives
BR0210886A (pt) Composto, composição farmacêutica, uso de um composto, e, métodos de geração de imagens, de monitoração do efeito do tratamento de um corpo humano ou animal com uma droga para combater uma condição associada com câncer e de tratamento de câncer ou de uma doença relacionada em um corpo humano ou animal
NZ609493A (en) Diagnosis and treatments relating to th2 inhibition
EA201590833A1 (ru) Антитела для лечения и профилактики болезни альцгеймера и их применение
MX2011010353A (es) Composicion farmaceutica.
NZ595262A (en) Use of il-23 and il-27 antagonists to treat autoimmune ocular inflammatory disease
DK1915620T3 (da) Diagnose, behandling og prævention af vaskulære sygdomme ved hjælp af IL-1alpha-autoantistoffer
UA109633C2 (uk) Антитіло людини проти тканинного фактора
WO2001075454A3 (en) Diagnosis and treatment of alzheimer's disease
EA200971131A1 (ru) Биомаркеры для прогнозирования чувствительности или отсутствия чувствительности к анти-фно агентам
BR112022004986A2 (pt) Anticorpos anti-tnfr2 e métodos de uso
EP1855719A4 (de) Neutralisierende monoklonale antikörper gegen coronaviren in zusammenhang mit schwerem akutem atemwegssyndrom
UA99094C2 (ru) Способ лечения пациента с системной красной волчанкой
Maddali-Bongi et al. Impact of hand and face disabilities on global disability and quality of life in systemic sclerosis patients
TW200716172A (en) Pharmaceutical compositions for treating lower motor neuron diseases
RU2008116567A (ru) Биомаркеры
DE60137264D1 (de) Monoklonale antikörper und zelloberflächenantigene zum nachweis und zur behandlung von kleinzelligem lungenkrebs (sclc)
EA201591219A1 (ru) Антитела против lamp1 и конъюгаты антитела и лекарственного средства, а также их применение
ES2619569T3 (es) Método de ensayo de infección o inflamación de las vías respiratorias inferiores

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties